BACK
Project/Company Name
Homing Therapeutics Limited 皓明醫藥
Project Leader
Source of Funding/Programme
TSSSU
Description
Our start-up positions as a “pipeline company” to develop and commercialize products that could navigate therapeutic immune cells to site of cancer maintenance for effective tumor killing. Utilizing synthetic biology and chemical approaches, we couple or induce homing receptors on CAR T cells to improve their bone marrow accessibility, thereby allowing sufficient immune-tumor contacts for early disease eradication. The new technologies will be initially applied to chimeric antigen receptor (CAR) T cells for treating blood cancers including leukemia, lymphoma and myeloma, and will be further succeeded into solid tumors and other forms of cell therapies.
Project/Company Name
Homing Therapeutics Limited 皓明醫藥
Project Leader
Source of Funding/Programme
TSSSU
Description
Our start-up positions as a “pipeline company” to develop and commercialize products that could navigate therapeutic immune cells to site of cancer maintenance for effective tumor killing. Utilizing synthetic biology and chemical approaches, we couple or induce homing receptors on CAR T cells to improve their bone marrow accessibility, thereby allowing sufficient immune-tumor contacts for early disease eradication. The new technologies will be initially applied to chimeric antigen receptor (CAR) T cells for treating blood cancers including leukemia, lymphoma and myeloma, and will be further succeeded into solid tumors and other forms of cell therapies.
Logo
Starting Year
2025
Business Area
Biotech
Nature
TSSSU Company